U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06846268) titled 'Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer' on Feb. 24.
Brief Summary: This is a single site, open-label, single-arm phase II study to determine feasibility, tolerability, and preliminary efficacy of neoadjuvant ADG126 and pembrolizumab in stage II or III colorectal cancer.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Locally Advanced Colorectal Cancer
Intervention:
DRUG: ADG126
Administered via intravenous infusion on Day 1 only (Q6W) or Day 1 and Day 22 (Q3W).
DRUG: Pembrolizumab
Administered via intravenous infusion on Day 1 and Day 22.
Recruitment Status: NOT_YET_RECR...